Simris Alg AB (publ) (SIMRIS-B.ST)
SEK 0.09
(0.21%)
SEK 0.09
(0.21%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 85.07 Million SEK | 4661.66% |
| 2022 | -1.86 Million SEK | -186.02% |
| 2021 | 2.16 Million SEK | 117.31% |
| 2020 | -12.52 Million SEK | -296.86% |
| 2019 | -3.15 Million SEK | -348.51% |
| 2018 | 1.26 Million SEK | 279.87% |
| 2017 | -705.83 Thousand SEK | 97.16% |
| 2016 | -24.89 Million SEK | -35.77% |
| 2015 | -18.33 Million SEK | -277.54% |
| 2014 | -4.85 Million SEK | -84.88% |
| 2013 | -2.62 Million SEK | 45.52% |
| 2012 | -4.82 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 91.02 Million SEK | -3.12% |
| 2024 Q1 | 93.95 Million SEK | 10.43% |
| 2023 Q4 | 85.07 Million SEK | 12.71% |
| 2023 Q3 | 75.47 Million SEK | -20.11% |
| 2023 Q1 | 90.76 Million SEK | 4966.7% |
| 2023 Q2 | 94.48 Million SEK | 4.1% |
| 2023 FY | 85.07 Million SEK | 4661.66% |
| 2022 FY | -1.86 Million SEK | -186.02% |
| 2022 Q4 | -1.86 Million SEK | -102.17% |
| 2022 Q3 | 86.02 Million SEK | 607.96% |
| 2022 Q2 | -16.93 Million SEK | -2754.39% |
| 2022 Q1 | 638 Thousand SEK | -70.57% |
| 2021 Q2 | -1.7 Million SEK | 72.28% |
| 2021 Q3 | 269 Thousand SEK | 115.79% |
| 2021 FY | 2.16 Million SEK | 117.31% |
| 2021 Q1 | -6.14 Million SEK | 50.9% |
| 2021 Q4 | 2.16 Million SEK | 705.95% |
| 2020 Q3 | -7.75 Million SEK | -3502.19% |
| 2020 Q2 | 228 Thousand SEK | -84.64% |
| 2020 FY | -12.52 Million SEK | -296.86% |
| 2020 Q4 | -12.52 Million SEK | -61.42% |
| 2020 Q1 | 1.48 Million SEK | 147.04% |
| 2019 Q3 | 3.74 Million SEK | 379.9% |
| 2019 FY | -3.15 Million SEK | -348.51% |
| 2019 Q4 | -3.15 Million SEK | -184.18% |
| 2019 Q2 | 780.99 Thousand SEK | 6.69% |
| 2019 Q1 | 732 Thousand SEK | -42.34% |
| 2018 Q4 | 1.26 Million SEK | 107.2% |
| 2018 FY | 1.26 Million SEK | 279.87% |
| 2018 Q1 | 4.03 Million SEK | 670.95% |
| 2018 Q2 | 4.33 Million SEK | 7.62% |
| 2018 Q3 | -17.62 Million SEK | -506.41% |
| 2017 Q4 | -705.83 Thousand SEK | 90.1% |
| 2017 FY | -705.83 Thousand SEK | 97.16% |
| 2017 Q1 | -20.43 Million SEK | 17.91% |
| 2017 Q2 | -14.2 Million SEK | 30.52% |
| 2017 Q3 | -7.13 Million SEK | 49.78% |
| 2016 Q2 | -48.89 Million SEK | -149.9% |
| 2016 FY | -24.89 Million SEK | -35.77% |
| 2016 Q1 | -19.56 Million SEK | -6.7% |
| 2016 Q4 | -24.89 Million SEK | 39.81% |
| 2016 Q3 | -41.36 Million SEK | 15.4% |
| 2015 Q4 | -18.33 Million SEK | 0.0% |
| 2015 Q1 | 4.86 Million SEK | 0.0% |
| 2015 FY | -18.33 Million SEK | -277.54% |
| 2014 FY | -4.85 Million SEK | -84.88% |
| 2013 FY | -2.62 Million SEK | 45.52% |
| 2012 FY | -4.82 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Asarina Pharma AB (publ) | -2.16 Million SEK | 4036.835% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 125.501% |
| NextCell Pharma AB | -46.79 Million SEK | 281.821% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 389.538% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 48.774% |
| AcouSort AB (publ) | -23.98 Million SEK | 454.686% |
| OncoZenge AB (publ) | -12.62 Million SEK | 773.755% |
| Xintela AB (publ) | -7.8 Million SEK | 1189.448% |
| Ziccum AB (publ) | -2.13 Million SEK | 4081.048% |
| Active Biotech AB (publ) | -33.2 Million SEK | 356.25% |
| Alzinova AB (publ) | -21.22 Million SEK | 500.806% |
| Amniotics AB (publ) | -5.63 Million SEK | 1610.565% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 270.079% |
| BioArctic AB (publ) | -606.58 Million SEK | 114.025% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | -1475.463% |
| Camurus AB (publ) | -1.16 Billion SEK | 107.3% |
| Cantargia AB (publ) | -139.74 Million SEK | 160.878% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | 9317.226% |
| CombiGene AB (publ) | -101.44 Million SEK | 183.867% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 203.641% |
| Genovis AB (publ.) | -43.94 Million SEK | 293.612% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 201.593% |
| Mendus AB (publ) | -96.29 Million SEK | 188.349% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 161.583% |
| Kancera AB (publ) | -45.69 Million SEK | 286.192% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 203.495% |
| LIDDS AB (publ) | -13.51 Million SEK | 729.626% |
| Lipum AB (publ) | -8.46 Million SEK | 1105.021% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 366.467% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | -59.846% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | 546.354% |
| Saniona AB (publ) | 40.44 Million SEK | -110.337% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 165.698% |
| Intervacc AB (publ) | -88.16 Million SEK | 196.501% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 270.375% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | -314.798% |
| Corline Biomedical AB | -17.01 Million SEK | 600.088% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 201.591% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 316.025% |
| Aptahem AB (publ) | 2.9 Million SEK | -2824.904% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 125.854% |
| Fluicell AB (publ) | -2.76 Million SEK | 3179.081% |
| Biovica International AB (publ) | -58.73 Million SEK | 244.841% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 288.148% |
| Abliva AB (publ) | -57.24 Million SEK | 248.629% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 143.695% |
| 2cureX AB (publ) | -13.4 Million SEK | 734.746% |
| I-Tech AB | -83.26 Million SEK | 202.177% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 36.845% |
| Cyxone AB (publ) | -16.67 Million SEK | 610.348% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 252.23% |
| Biosergen AB | -1.88 Million SEK | 4618.056% |
| Nanologica AB (publ) | -9.38 Million SEK | 1006.21% |
| SynAct Pharma AB | -61.75 Million SEK | 237.755% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 497.268% |
| BioInvent International AB (publ) | -236.3 Million SEK | 136.002% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | 743.086% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 227.129% |
| Pila Pharma AB (publ) | -5.18 Million SEK | 1742.083% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | 509.152% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | 2962.55% |